Hepatocellular Carcinoma Panel
Hepatocellular Carcinoma blood test panel measuring key tumor markers and liver context labs to support surveillance and trend-based interpretation.
This panel bundles multiple biomarker tests in one order—your report explains how results fit together.
This is a lab panel, meaning you get several related blood tests in one order. The Hepatocellular Carcinoma (HCC) Panel is designed to support liver-cancer surveillance and follow-up by looking at tumor markers together (not in isolation) and pairing them with liver context labs that help explain why a marker might move.
Do I need this panel?
You might consider an HCC panel if you are already in a higher-risk group for hepatocellular carcinoma, such as having cirrhosis from any cause, chronic hepatitis B, prior hepatitis C with advanced fibrosis, or a history of liver lesions that require ongoing surveillance.
This panel can also be useful when you have an abnormal ultrasound/CT/MRI finding and your clinician is trying to clarify risk while planning next steps. In that situation, tumor markers can add context, but they do not replace imaging or biopsy decisions.
If your anxiety is coming from a single mildly elevated tumor marker, this panel can help you avoid overreacting to one number by showing whether multiple markers move together and whether liver inflammation or impaired liver function could be contributing.
Your results are meant to support clinician-directed care and surveillance planning. This panel is not a stand-alone way to diagnose or rule out liver cancer.
Tumor markers can vary by lab method and are best interpreted by trends over time and in the context of imaging and liver disease severity.
Lab testing
Order the Hepatocellular Carcinoma Panel
Schedule online, results typically within about a week
Clear reporting and optional clinician context
HSA/FSA eligible where applicable
Get this panel with Vitals Vault
Vitals Vault makes it straightforward to order an HCC lab panel when you want a structured way to track tumor markers over time. Instead of chasing one-off tests, you can use a consistent panel to compare results across draws.
After your labs, you can use PocketMD to review your results as a pattern: which markers are stable, which are changing, and what liver-context labs suggest about inflammation, cholestasis (bile flow issues), or reduced liver synthetic function. That context matters because benign liver injury can shift tumor markers.
If you are in surveillance, repeating the same panel on a schedule recommended by your clinician can make trend interpretation clearer than switching between different test sets. If parallel inflammatory activity monitoring is part of your plan, you can also add an inflammation-focused panel at checkout.
- Designed for trend-based monitoring rather than one-off interpretation
- Supports pairing tumor markers with liver context labs
- PocketMD can help you prepare questions for your clinician and imaging follow-up
Key benefits of the Hepatocellular Carcinoma Panel
- Checks multiple HCC-associated tumor markers together so you can interpret patterns instead of a single isolated value.
- Supports surveillance in higher-risk liver disease by making it easier to track marker trends over time.
- Adds liver context labs that can help explain false positives from inflammation, cholestasis, or reduced liver function.
- Helps you and your clinician decide whether a change is likely meaningful or more consistent with benign liver injury.
- Reduces “number anxiety” by showing whether elevations are broad, consistent, and persistent across markers.
- Creates a consistent baseline before treatment, procedure follow-up, or a new imaging finding.
- Improves the quality of follow-up conversations by organizing results into a clear, repeatable panel.
What is the Hepatocellular Carcinoma Panel?
The Hepatocellular Carcinoma (HCC) Panel is a bundled set of blood tests used to support liver-cancer surveillance and evaluation. It typically includes tumor markers associated with HCC—most commonly alpha-fetoprotein (AFP) and related fractions—plus additional markers that may improve specificity in certain settings.
Because tumor markers can rise for reasons other than cancer, a well-designed HCC panel also includes liver function and liver injury tests. These help you interpret whether a marker change might be occurring alongside hepatitis flares, alcohol-related injury, fatty liver inflammation, bile duct obstruction, or reduced liver synthetic function.
It is important to know what this panel can and cannot do. Tumor markers are not a screening replacement for imaging, and normal markers do not guarantee the absence of HCC. The most useful way to use this panel is to combine it with your risk profile and imaging plan and to focus on trends—persistent rises, multi-marker concordance, and changes that do not match the degree of liver injury.
If you already have a known liver lesion, the panel may be used as one piece of follow-up, but imaging characteristics and clinical judgment remain central.
What do my panel results mean?
Lower or undetectable tumor markers across the panel
When AFP and other HCC-associated tumor markers are low or not elevated, that is generally reassuring, especially if they are stable over time. In surveillance, the most helpful signal is consistency: a stable pattern across multiple draws makes a sudden cancer-related surge less likely. However, low markers do not rule out HCC, particularly early tumors or certain tumor subtypes that do not produce much marker. If imaging is abnormal, your clinician may still recommend close follow-up even when the panel looks “quiet.”
Stable markers with liver context labs that match your baseline
An “optimal” pattern is usually one where tumor markers are within the reference range (or at your personal baseline) and liver context labs are not showing a new spike in injury or a new drop in liver synthetic function. This combination supports a surveillance approach focused on routine imaging intervals and repeat labs on a schedule that fits your risk level. If you have chronic liver disease, your best comparison is often your own prior results rather than a single population reference range.
Elevations or upward trends—especially when multiple markers move together
Higher results can mean different things depending on the pattern. A mild, isolated AFP rise with clear signs of liver inflammation (for example, rising ALT/AST) can occur with hepatitis flares, alcohol-related injury, or other benign liver stress. A more concerning pattern is a persistent upward trend over serial tests, particularly if multiple tumor markers rise together and the increase is not explained by a parallel change in liver injury labs. Any significant elevation or accelerating trend should be interpreted alongside recent imaging and your clinical history, and it often triggers earlier repeat imaging or specialist review rather than immediate conclusions.
Factors that influence HCC panel markers
Tumor markers are influenced by more than cancer. Active hepatitis (viral, autoimmune, or metabolic), recent heavy alcohol use, liver regeneration after injury, and cholestasis can shift marker levels. Reduced liver clearance in advanced cirrhosis can also affect how markers behave over time. Non-liver conditions (including certain germ cell tumors or pregnancy for AFP) can raise specific markers. Medications, supplements, and recent procedures can change liver enzymes and bilirubin, which can make a tumor marker look more alarming than it is. The most practical approach is to interpret your panel as a whole: tumor markers plus liver injury (ALT/AST), cholestasis (ALP/GGT, bilirubin), and synthetic function (albumin, INR if available) together with imaging timing.
What’s included in this panel
- Afp
- Afp L3
- Dcp (Des Gamma Carboxy Prothrombin)
Frequently Asked Questions
Can this panel diagnose hepatocellular carcinoma (HCC)?
No. This panel supports risk assessment and surveillance, but it cannot diagnose HCC by itself. Imaging (ultrasound, CT, or MRI) and clinical evaluation are central, and biopsy is sometimes needed. Tumor markers are best used to add context and track trends.
What is the difference between AFP, AFP-L3%, and DCP (PIVKA-II)?
AFP is the most commonly used HCC-associated marker but can rise with non-cancer liver injury. AFP-L3% is a fraction of AFP that may be more associated with HCC in some contexts. DCP (also called PIVKA-II) is another marker that can complement AFP. Your clinician typically interprets them together and focuses on trends and concordance across markers.
Do I need to fast for this panel?
Fasting is usually not required for tumor markers and most liver function tests. If you are combining this panel with other labs (like lipids or glucose/insulin testing), fasting may be recommended for the combined order. Follow the collection instructions provided with your lab order.
Why can tumor markers be elevated when I don’t have cancer?
False positives happen. AFP can rise with hepatitis flares, cirrhosis, and liver regeneration after injury. Cholestasis and reduced liver clearance can also affect lab patterns. That is why this panel pairs tumor markers with liver context labs and why repeat testing and imaging timing matter.
How often should I repeat an HCC panel?
The right interval depends on your risk level and your imaging plan. Many surveillance strategies use regular imaging (often every 6 months in higher-risk groups), and labs may be repeated on a similar cadence or sooner if a marker changes or imaging is indeterminate. Your clinician should set the schedule based on your history.
Is it better to order the panel instead of ordering AFP alone?
If you are using labs for surveillance or follow-up, a panel can be more informative than AFP alone because it helps you interpret whether changes are isolated or part of a broader pattern and whether liver injury or cholestasis might be contributing. AFP alone can be useful in some situations, but it is easier to misread without context.
What should I do if one marker is mildly high but the others are normal?
A single mild elevation is often a prompt to look for context rather than to assume the worst. Review whether liver enzymes or bilirubin changed at the same time, consider recent illness, alcohol intake, medication changes, or hepatitis activity, and compare to your prior baseline. Your clinician may recommend repeating the panel and/or adjusting imaging timing to clarify whether the change persists.